All Episodes

Jupiter Neurosciences (JUNS): Jotrol’s Bioavailability Breakthrough and the Key Parkinson’s Phase 2A Readout

NurExone Biologic (NRX): The Inhibitor of the Inhibitor: How Nurexone's ExoPTEN Is Designed to Restart Nerve Regeneration

PharmAla Biotech (MDMA): Two Transactions, One Strategy: Unlocking Pipeline Value Through Structured Partnerships

Solvonis Therapeutics (SVNS): CSO Professor David Nutt on Solvonis' Approach to Resetting the Addicted Brain

Solvonis Therapeutics (SVNS): Rewriting the Standard of Care for Severe Alcohol Use Disorder

PetVivo Holdings (PETV): The Trifecta: Regenerative Science, AI-Enabled Vet Care, and Human Translation

SBC Medical (SBC): Scaling Aesthetics, Longevity, and Global Growth

ExoZymes (EXOZ): Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturing

Hidden Gems - Unlocking Value in Biotech's Most Overlooked Stocks

Vivos Therapeutics (VVOS): 2025 Results and Path to Cash Flow Breakeven by End-2026

Trump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors

WTR Insights Conference Preview: Nurexone's Nerve Regeneration & Anixa's Cancer Immunotherapy in Focus

Circular Genomics: Cracking the Brain Code with Circular RNA

Unmasking the Treatment Landscape for Obstructive Sleep Apnea (OSA)

Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment

Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year

Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision

Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era

Medicus Pharma (MDCX): De‑Risking Drug Development to Capture a High‑Growth Market Opportunity

NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech

Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity

How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker

Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors

The lure of the NASDAQ for Biotechs

Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease

Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other

CEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain Barrier

RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers

Vivos Therapeutics’ Mission to Transform Sleep Treatment

GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders

Ainos' Director of Corporate Development Jack Lu Discusses the AI Nose Platform' continuing 2025 momentum and Looks Ahead into 2026

The Psychedelic Investment Environment: A New Era of Optimism

Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation

Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries

PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL

CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors

Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market

Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting

Transforming Global Healthcare Access: Doc.com’s Mission for Free Basic Telemedicine

Psychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market Outlook

Ludwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic Tool

CEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing Health

Ainos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AI

Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer

Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments

A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape

Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough

How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions

Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market

Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data

Most-Favored-Nation Drug Pricing Lacks Executive Plan

Current State of Biotech, Market Pressure Points, Obesity and PD-1/VEGF

WTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOC

Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps

Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs

OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps

Launch of WTR Biotech Spotlight Podcast with Tim Gerdeman and Do Kim